Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

8.09
+0.51006.73%
Post-market: 8.110.0209+0.26%19:58 EDT
Volume:7.21M
Turnover:58.70M
Market Cap:837.99M
PE:-1.55
High:8.40
Open:7.79
Low:7.75
Close:7.58
Loading ...

Intellia Therapeutics: Hold Rating Amid Regulatory Challenges and Strategic Consolidation

TIPRANKS
·
09 May

Intellia Therapeutics: Promising CRISPR-Based Therapies Drive Buy Rating Amid Clinical Advancements

TIPRANKS
·
09 May

BUZZ-U.S. STOCKS ON THE MOVE-Tapestry, Carvana, PPG Industries

Reuters
·
08 May

BUZZ-Intellia Therapeutics rises on narrower Q1 loss

Reuters
·
08 May

Stock Track | Intellia Therapeutics Soars 10.84% on Strong Q1 Results and Extended Cash Runway

Stock Track
·
08 May

Intellia Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May

Stock Track | Intellia Therapeutics Soars 5.49% Pre-market on Strong Q1 Results and Extended Cash Runway

Stock Track
·
08 May

Intellia Therapeutics Ended Q1 2025 With Approximately $707.1M In Cash, Cash Equivalents And Marketable Securities; Expected To Fund Operations Into 1H Of 2027

Benzinga
·
08 May

Intellia Therapeutics Q1 2025 EPS $(1.10) Beats $(1.27) Estimate, Sales $16.63M Beat $11.87M Estimate

Benzinga
·
08 May

Intellia Therapeutics Inc: Expects to Fund Operations Into First Half of 2027

THOMSON REUTERS
·
08 May

Intellia Therapeutics Inc: Ended Q1 With About $707.1 Mln in Cash, Cash Equivalents & Marketable Securities

THOMSON REUTERS
·
08 May

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks
·
05 May

Director Muna Bhanji Reports Disposal of Common Shares of Intellia Therapeutics Inc

Reuters
·
02 May

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

Zacks
·
01 May

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

Dow Jones
·
22 Apr

Intellia Therapeutics Raised to Outperform From Peer Perform by Wolfe Research

Dow Jones
·
22 Apr

Intellia Therapeutics Shares Rise After Upgrade From Wolfe Research

MT Newswires Live
·
22 Apr

Intellia Therapeutics upgraded at Wolfe on sentiment, valuation

TIPRANKS
·
21 Apr

Wolfe Research Upgrades Intellia Therapeutics to Outperform From Peer Perform, Price Target is $21

MT Newswires Live
·
21 Apr

Intellia Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research

TIPRANKS
·
21 Apr